TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7930300

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 25 micrograms twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 micrograms twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2467119

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30282584

Group type: EXPERIMENTAL
Intervention: GFR-based classifier
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: ACSP75 and ACSP-scores
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CAD238-score
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: CKD273
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard risk factors (age and GFR)
Number of subjects: 151
Study: 27865696

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretch Control (SC)
Number of subjects: 30
Study: 26230989

Group type: EXPERIMENTAL
Intervention: Acupuncture and Bee Venom Acupuncture (BVA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 11
Study: 24001247

Group type: EXPERIMENTAL
Intervention: Natural Frequency (NF) framing
Number of subjects: 325

Group type: COMPARATOR
Intervention: Conditional Probability (CP) framing
Number of subjects: 325
Study: 21925942

Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (Klearway - K or Silencer - S)
Number of subjects: 15
Study: 18371542

Group type: EXPERIMENTAL
Intervention: CB + HB education program
Number of subjects: 132

Group type: COMPARATOR
Intervention: CB education
Number of subjects: 132
Study: 16634750

Group type: EXPERIMENTAL
Intervention: Color duplex sonography (CDS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 144
Study: 14669926

Group type: EXPERIMENTAL
Intervention: deer antler velvet powder
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: deer antler velvet extract
Number of subjects: 38

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study: 11089392

Group type: EXPERIMENTAL
Intervention: Best fitting mask (selected from different sizes and different brands)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Selected mask (only one brand but selected from different sizes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard mask
Number of subjects: 20
Study: 8867722

Group type: COMPARATOR
Intervention: Iron supplementation during pregnancy
Number of subjects: 7241

Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 7241

Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 7241

Group type: EXPERIMENTAL
Intervention: Intrauterine devices
Number of subjects: 7241

Group type: EXPERIMENTAL
Intervention: Blood donation
Number of subjects: 7241

Group type: COMPARATOR
Intervention: Non-blood donors
Number of subjects: 7241
Study: 1628637

Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia with propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced volatile anaesthesia with enflurane
Number of subjects: 60
Study: 29952698

Group type: EXPERIMENTAL
Intervention: Hop stabilization training (supervised exercises 3 times per week for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hop stabilization training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 29128523

Group type: EXPERIMENTAL
Intervention: Cigarette trial (participants smoked two cigarettes of their brand within 15min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham trial (participants held the cigarette without lighting it)
Number of subjects: 14
Study: 27187851

Group type: EXPERIMENTAL
Intervention: Stepwise psychotherapy (UC-PT)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Usual care plus one information session (UC-IS)
Number of subjects: 570
Study: 25012727

Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide (300, 600, or 900 μg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intramuscular pasireotide long-acting release (20, 40, or 60 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intramuscular pasireotide long-acting release
Number of subjects: 45
Study: 21296033

Group type: EXPERIMENTAL
Intervention: SITU-LRYGB
Number of subjects: 140

Group type: COMPARATOR
Intervention: 5-port LRYGB
Number of subjects: 140
Study: 20142215

Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve (MCV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN (ES)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both MCV and ES
Number of subjects: 45
Study: 17143047

Group type: EXPERIMENTAL
Intervention: Dietary vitamin K intake of more than 250 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80% decrease in vitamin K intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake by 100 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Over-the-counter multivitamin supplements containing vitamin K1
Number of subjects: 0
Study: 16274381

Group type: EXPERIMENTAL
Intervention: 0.25 mg 17‐beta estradiol for 36 months
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo for 36 months
Number of subjects: 167
Study: 12018742

Group type: EXPERIMENTAL
Intervention: High Dose Therapy (HDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Chemotherapy (CCT)
Number of subjects: 0
Study: 10789356

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 7587973

Group type: EXPERIMENTAL
Intervention: AUDADIS alcohol module
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AUDADIS drug module
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AUDADIS diagnoses
Number of subjects: 0
Study: 2078484

Group type: EXPERIMENTAL
Intervention: Continuation of CMF until progression (A)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intensification-discontinuation arm (B)
Number of subjects: 198
Study: 447898

Group type: EXPERIMENTAL
Intervention: Alcoholic beverages
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 72

Group type: COMPARATOR
Intervention: No beverages
Number of subjects: 72
Study: 29749718

Group type: EXPERIMENTAL
Intervention: Test acetaminophen product available in Mexico
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference 500‐mg acetaminophen product
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 28
Study: 28600815

Group type: EXPERIMENTAL
Intervention: Neutral zone (NZ) mandibular dentures
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional (CV) mandibular dentures
Number of subjects: 35
Study: 24728665

Group type: EXPERIMENTAL
Intervention: Peretinoin 600 mg/day
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Peretinoin 300 mg/day
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 23668921

Group type: EXPERIMENTAL
Intervention: Postoperative subacromial infusion catheter filled with 0.5% bupivacaine without epinephrine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Postoperative subacromial infusion catheter filled with saline solution
Number of subjects: 88

Group type: COMPARATOR
Intervention: No postoperative subacromial infusion catheter
Number of subjects: 88

Group type: COMPARATOR
Intervention: Mean daily oxycodone consumption
Number of subjects: 88
Study: 21545606

Group type: EXPERIMENTAL
Intervention: A3309 (0.1-10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19644896

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 17380548

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) 200/0.62 kDa
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) 130/0.4 kDa
Number of subjects: 62

Group type: COMPARATOR
Intervention: 4% Gelatine
Number of subjects: 62
Study: 15500197

Group type: EXPERIMENTAL
Intervention: 1000 mg acetylsalicylic acid (ASA) + 60 mg pseudoephedrine (PSE)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: 500 mg ASA + 30 mg PSE
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol + 60 mg PSE (active control)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study: 11222797

Group type: EXPERIMENTAL
Intervention: Add-on trials
Number of subjects: 9144

Group type: EXPERIMENTAL
Intervention: Monotherapy initiation trials
Number of subjects: 9144
Study: 9034984

Group type: COMPARATOR
Intervention: Meloxicam 15 mg once daily
Number of subjects: 468

Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg once daily
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 468
Study: 7946584

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation treatment
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Induction treatment (at 8 months)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (after 3 months)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Limited erythema at presentation
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Complete regression of inflammatory symptoms (at 8 months)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Tumour regression (at 3 months)
Number of subjects: 223
Study: 3228991

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anaesthetics (EMLA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study: 30678556

Group type: EXPERIMENTAL
Intervention: High-ending tune (L*+H L‐!H%)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Flat-ending tune (L+H* L‐L%)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-ending questions
Number of subjects: 4
Study: 31793485

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine based (Consepsis)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 ppm ozonated water (TeknO3zone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5% boric acid (Handmade)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no disinfectant)
Number of subjects: 120
Study: 28808915

Group type: EXPERIMENTAL
Intervention: Posaconazole tablets
Number of subjects: 100
Study: 25760679

Group type: EXPERIMENTAL
Intervention: Phenylephrine (100 μg + 0.5 μg kg(‐1) min(‐1))
Number of subjects: 60
Study: 23796191

Group type: EXPERIMENTAL
Intervention: Stepped care intervention (20-minute session of behavioural change counselling, with potential referral to motivational enhancement therapy and local specialist alcohol services)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Stepped care intervention
Number of subjects: 529

Group type: COMPARATOR
Intervention: Minimal intervention (5-minute brief advice intervention)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 529
Study: 21362268

Group type: EXPERIMENTAL
Intervention: Minichromosome maintenance complex component 2 (MCM2)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Cyclin A
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Mismatch repair deficiency
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Transforming growth factor β receptor type II (TGFBRII) overexpression
Number of subjects: 790
Study: 20205022

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Reading a Newspaper (RN)
Number of subjects: 65
Study: 17892984

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study: 15277959

Group type: EXPERIMENTAL
Intervention: TENS-R
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional TENS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Placement of TENS electrodes on the back
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placement of TENS electrodes on the legs
Number of subjects: 13
Study: 11210993

Group type: EXPERIMENTAL
Intervention: Inhaled insulin plus bedtime subcutaneous ultralente insulin injection
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual insulin regimen of two to three injections per day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 73
Study: 9701387

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg 3 times per day)
Number of subjects: 21
Study: 8027275

Group type: EXPERIMENTAL
Intervention: Buserelin (twice a day for 15 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Triptorelin (3.75 mg single dose 15 days before stimulation)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triptorelin (0.1 mg daily for 4 weeks before stimulation)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All protocols (A, B, C)
Number of subjects: 90
Study: 2563730

Group type: EXPERIMENTAL
Intervention: BIM 23014 (500 micrograms, sc)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIM 23014 (250 micrograms, sc)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIM 23014 (125 micrograms, sc)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIM 23014 (2 mg/12 h, constant sc infusion)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIM 23014 (2 mg/12 h, constant sc infusion) with GHRH (10 ng/kg.min iv)
Number of subjects: 16
Study: 5039779

Group type: EXPERIMENTAL
Intervention: Review at a preadmission clinic
Number of subjects: 99

Group type: COMPARATOR
Intervention: Direct admission to a hospital bed
Number of subjects: 99
Study: 29304831

Group type: EXPERIMENTAL
Intervention: Educational video plus telecare (protocol-guided follow-up telephone call)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Educational video only
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 28453969

Group type: EXPERIMENTAL
Intervention: usual care plus cognitive task procedure (visuospatial task using 'Tetris' for 15 minutes within six hours after ECS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 56
Study: 26580673

Group type: EXPERIMENTAL
Intervention: SmartCare™ weaning
Number of subjects: 70

Group type: COMPARATOR
Intervention: Respiratory physiotherapy-driven weaning
Number of subjects: 70
Study: 24238397

Group type: EXPERIMENTAL
Intervention: SMS reminders (daily messages reminding them of aspects regarding taking their medication)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 1198
Study: 21068341

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 4128
Study: 18307223

Group type: EXPERIMENTAL
Intervention: Angio-Seal (AS)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: StarClose (SC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 450
Study: 16935174

Group type: EXPERIMENTAL
Intervention: 10 U of botulinum toxin A (BTX‐A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 U of botulinum toxin A (BTX‐A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 30
Study: 12951885

Group type: EXPERIMENTAL
Intervention: 100 g glucose ingestion during oral glucose tolerance test
Number of subjects: 50
Study: 9500558

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 60
Study: 7632121

Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple‐family group treatment
Number of subjects: 172

Group type: COMPARATOR
Intervention: Psychoeducational single‐family treatment
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 172
Study: 2565687

Group type: EXPERIMENTAL
Intervention: Isradipine alone (1.25 and 2.5 mg twice daily)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Isradipine with guanfacine (1 mg daily after 8 weeks)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Isradipine alone
Number of subjects: 212

Group type: COMPARATOR
Intervention: Isradipine with guanfacine
Number of subjects: 212
Study: 836732

Group type: EXPERIMENTAL
Intervention: Structured questionnaire record
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard case notes
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Surgical operation as a result of investigation
Number of subjects: 278
Study: 31432381

Group type: EXPERIMENTAL
Intervention: Family Spirit intervention
Number of subjects: 322
Study: 28918754

Group type: EXPERIMENTAL
Intervention: MALS diagnosis based on hemophagocytic syndrome score and/or hepatobiliary dysfunction and disseminated intravascular coagulation
Number of subjects: 5121

Group type: EXPERIMENTAL
Intervention: Ferritin level above 4420 ng/ml
Number of subjects: 5121

Group type: EXPERIMENTAL
Intervention: Ferritin measurements on day 3
Number of subjects: 5121
Study: 25038558

Group type: EXPERIMENTAL
Intervention: Implementation of diabetes management protocols using certified diabetes educators (CDEs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15
Study: 21940989

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 729

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 729
Study: 19116322

Group type: EXPERIMENTAL
Intervention: 1.05 g E-EPA/d plus 0.15 g ethyl-docosahexaenoic acid/d (n = 59)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (n = 61)
Number of subjects: 120
Study: 17574821

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study: 15342847

Group type: EXPERIMENTAL
Intervention: Maternal psychological distress at 40 weeks gestation
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Maternal cigarette smoking during pregnancy
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 869
Study: 11161541

Group type: EXPERIMENTAL
Intervention: Regimen A (parenteral nutrition without lipids)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regimen B (parenteral nutrition with lipids)
Number of subjects: 10
Study: 9550543

Group type: EXPERIMENTAL
Intervention: Selective β1‐adrenoceptor antagonist atenolol (0.062 mg · kg‐1 body weight) administered immediately after exercise (EXAT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Nonselective β‐adrenoceptor antagonist propranolol (0.15 mg · kg‐1 body weight) administered after exercise (EXPRO)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Saline injection instead of β‐antagonist (EX)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control with selective β1‐adrenoceptor antagonist atenolol (REAT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control with nonselective β‐adrenoceptor antagonist propranolol (REPRO)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control with saline (RE)
Number of subjects: 7
Study: 7917532

Group type: EXPERIMENTAL
Intervention: Clodronate (C)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 2679236

Group type: EXPERIMENTAL
Intervention: Nicardipine (NIC) treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIC treatment group with impaired LV function
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with impaired LV function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIC treatment group
Number of subjects: 0
Study: 630909

Group type: EXPERIMENTAL
Intervention: 120 mg fenfluramine plus a 1600 calorie diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo plus a 1600 calorie diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 120 mg fenfluramine
Number of subjects: 15
Study: 31455398

Group type: EXPERIMENTAL
Intervention: Rigid wrist splint
Number of subjects: 112

Group type: COMPARATOR
Intervention: Soft wrist bandage (placebo)
Number of subjects: 112
Study: 27225284

Group type: EXPERIMENTAL
Intervention: Spiritual components training (10 sessions including components such as image of God, relationship with God, Tawwakul, searching for meaning during difficulties and pain)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 40
Study: 25257238

Group type: EXPERIMENTAL
Intervention: Mild- to moderate-intensity aerobic exercise training programme for six weeks during radiotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine care control group without special exercise intervention
Number of subjects: 58
Study: 23509160

Group type: EXPERIMENTAL
Intervention: Heliox
Number of subjects: 319

Group type: COMPARATOR
Intervention: Airox
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Heliox (facemask tolerant subgroup)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Airox (facemask tolerant subgroup)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Heliox (nasal cannula subgroup)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Airox (nasal cannula subgroup)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Heliox (subgroup started on CPAP)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Airox (subgroup started on CPAP)
Number of subjects: 319
Study: 20672256

Group type: EXPERIMENTAL
Intervention: Group music intervention (12 sessions of 30 minutes each, twice a week for 6 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 100
Study: 19769477

Group type: EXPERIMENTAL
Intervention: Music group (listening to preselected soft music for 15 minutes)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Aroma group (inhaling Citrus bergamia essential oil vapor for 15 minutes)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combined music and aroma group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 114